Hypothesis

Time-restricted eating (TRE) enhances the efficacy of senolytic drugs by metabolically priming senescent cells for AMPK‑dependent Bcl‑2 phosphorylation, lowering the apoptotic threshold and causing selective clearance beyond what either intervention achieves alone.

Mechanistic Rationale

• TRE activates hepatic and peripheral AMPK during fasting intervals, which phosphorylates Bcl‑2 at Ser70 (and Bcl‑xL at Ser62), converting these anti‑apoptotic proteins into pro‑apoptotic substrates or reducing their ability to bind Bax/Bak [2].
• Senescent cells exhibit heightened reliance on Bcl‑2/Bcl‑xL for survival [4], making them uniquely vulnerable when Bcl‑2 is inactivated.
• Dasatinib inhibits Src‑family kinases, while quercetin reduces Bcl‑xL stability; together they trigger apoptosis when the Bcl‑2/Bcl‑xL buffer is compromised [1].
• AMPK activation also raises NAD+ levels, stimulating SIRT1 deacetylation of p53 and FOXO, further promoting a pro‑apoptotic transcriptional program in senescent cells [5].

Thus, TRE creates a biochemical senescent‑cell‑specific "primed" state that synergizes with senolytic‑induced stress.

Experimental Design

Model: p16‑Ink4a‑luciferase reporter mice (aged 20 months) to longitudinally track senescent burden. Groups (n=15 per group):

1. Ad libitum fed control (AL)
2. TRE only (16 h daily fast)
3. Senolytics only (D+Q 5 mg/kg dasatinib + 50 mg/kg quercetin, weekly ×3)
4. TRE + Senolytics (same dosing, TRE maintained throughout)
5. Rapamycin + Acarbose (positive control for lifespan extension [7])

Intervention duration: 6 months. Readouts (collected at baseline, monthly, and endpoint):

• In vivo bioluminescence for p16‑Ink4a activity (senescent cell load).
• Plasma SASP cytokines (IL‑6, IL‑1β, VEGF) via ELISA.
• Tissue‑specific Bcl‑2 phosphorylation (Western blot of lysates from liver, adipose, kidney).
• AMPK activation (p‑AMPK Thr172).
• Functional healthspan: grip strength, treadmill endurance, frailty index.
• Survival curves.

Predicted Outcomes

• Primary: TRE+Senolytics group will show ≥50 % greater reduction in p16‑luciferase signal vs. Senolytics alone (p<0.01).
• Secondary: Greater decline in SASP cytokines and higher p‑AMPK/p‑Bcl‑2 ratios in liver and adipose.
• Tertiary: Median lifespan extension of ~20 % over Senolytics alone, approaching the additive effect seen with rapamycin+acarbose.
• Falsification: If TRE does not increase p‑Bcl‑2 phosphorylation or senolytic efficacy (no significant difference between TRE+Senolytics and Senolytics alone), the hypothesis is refuted.

Potential Pitfalls & Alternatives

• Compensatory upregulation of Mcl‑1 could blunt Bcl‑2 targeting; assess Mcl‑1 levels.
• TRE intensity may affect feeding‑induced hormesis; test 12 h vs 20 h fasting windows.
• Off‑target effects of dasatinib/quercetin on AMPK could confound; use AMPK‑deficient mice to verify dependence.

By directly linking a nutrient‑sensing kinase to the apoptotic threshold of senescent cells, this hypothesis provides a concrete, testable mechanism for why combining TRE with senolytics could surpass the sum of their parts and move toward the ambitious goal of extending human healthspan beyond 120 years.